Marcella Lanza

Title: Innovations by Marcella Lanza in Doxorubicin Conjugation

Introduction

Marcella Lanza is a notable inventor based in Bologna, Italy. She has made significant contributions to the field of biochemistry, particularly in the development of innovative processes for drug conjugation. Her work focuses on enhancing the efficacy and safety of therapeutic agents.

Latest Patents

Marcella Lanza holds a patent for a process titled "Process for the preparation of doxorubicin conjugates with lactosaminated human albumin." This innovative procedure involves conjugating hydrazone derivatives of doxorubicin, which have a maleimide terminal group, to lactosaminated human albumin (L-HSA). The method utilizes trialkylphosphines to reduce disulfide bonds in the protein, making the SH groups available for thioether bond formation. This approach offers advantages over traditional methods, as it can be performed under simple conditions without the need for an inert atmosphere or preliminary purification of the reduced L-HSA.

Career Highlights

Marcella Lanza is affiliated with the University of Bologna, where she conducts her research and development activities. Her work has garnered attention for its potential applications in cancer therapy, particularly in improving the delivery and effectiveness of doxorubicin.

Collaborations

Some of her notable collaborators include Luigi Fiume and Giuseppina Di Stefano. Their combined expertise contributes to the advancement of innovative solutions in the field of drug conjugation.

Conclusion

Marcella Lanza's contributions to the field of biochemistry, particularly through her patented process for doxorubicin conjugation, highlight her role as an influential inventor. Her work continues to pave the way for advancements in therapeutic applications.